Evidence map›Paper›PMID 39396510›Full record

ArticleOncology2025

MUC17 Is a Potential New Prognostic Biomarker and Promotes Pancreatic Cancer Progression in Obstructive Jaundice.

Eleonóra Gál, István Menyhárt, Zoltán Veréb, Lajos Kemény, László Tiszlavicz, Zoltán Márton Köhler, Anikó Keller-Pintér, Dávid Rakk, András Szekeres, Tamás Takács and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Eleonóra GálDepartment of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary.
István MenyhártDepartment of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary.
Zoltán VerébRegenerative Medicine and Cellular Pharmacology Research Laboratory, Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
Lajos KeményRegenerative Medicine and Cellular Pharmacology Research Laboratory, Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary.
László TiszlaviczDepartment of Pathology, University of Szeged, Szeged, Hungary.
Zoltán Márton KöhlerDepartment of Biochemistry, University of Szeged, Szeged, Hungary.
Anikó Keller-PintérDepartment of Biochemistry, University of Szeged, Szeged, Hungary.
Dávid RakkDepartment of Microbiology, University of Szeged, Szeged, Hungary.
András SzekeresDepartment of Microbiology, University of Szeged, Szeged, Hungary.
Tamás TakácsDepartment of Medicine, University of Szeged, Szeged, Hungary.
László CzakóDepartment of Medicine, University of Szeged, Szeged, Hungary.
Péter HegyiTranslational Pancreatology Research Group, Interdisciplinary Center of Excellence for Research Development and Innovation, University of Szeged, Szeged, Hungary.
Boshra YosefDepartment of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary.
Viktória VengloveczDepartment of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOur working group has previously shown that bile acids (BAs) accelerate carcinogenic processes in pancreatic cancer (PC) in which mucin 4 (MUC4) expression has a central role. However, the role of other mucins in PC is less clear, especially in bile-induced cancer progression. The study aim was to investigate expression of MUC17 in BA- or human serum-treated pancreatic ductal adenocarcinoma (PDAC) cell lines.

methodsDifferent cell-based assays with RNA silencing/overexpression were used to study the role of MUC17 in cancer progression. Protein expression of MUC17 was evaluated in 55 human pancreatic samples by immunohistochemistry, and Kaplan-Meier survival analysis was used to compare survival curves.

resultsExpression of MUC17 increased in PDAC patients, especially in obstructive jaundice (OJ), and the elevated MUC17 expression associated with poorer overall survival (10.66 ± 1.99 vs. 15.05 ± 2.03 months; log-rank: 0.0497). Treatment of Capan-1 and AsPC-1 cells with BAs or with human serum obtained from PDAC + OJ patients enhanced the expression of MUC17, as well as the proliferative potential of the cells, whereas knockdown of MUC17 alone or in combination with MUC4 decreased BAs-induced carcinogenic processes.

conclusionOur results demonstrated that MUC17 has a central role in bile-induced PC progression, and in addition to MUC4, this isoform also can be used as a novel prognostic biomarker.

Indexed as

Biomarkers, TumorCarcinoma, Pancreatic DuctalJaundice, ObstructiveMucinsPancreatic NeoplasmsAgedBile Acids and SaltsCell Line, TumorCell ProliferationDisease ProgressionFemaleHumansMaleMiddle AgedMucin-4PrognosisBile Acids and SaltsBiomarkers, TumorMUC4 protein, humanMucin-4MucinsBile acidsMUC17MUC4Obstructive jaundicePancreatic cancer

Identifiers

PMID39396510
PMCPMC12324704

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.